Pasi A. Jänne, M.D., Ph.D.
Professor of Medicine, Harvard Medical School
Director, Lowe Center for Thoracic Oncology
Dr. Janne earned his M.D. and Ph.D. from the School of Medicine at the University of Pennsylvania with an internship and residency in medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at Dana Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002 he earned a master’s degree in clinical investigation from Harvard University.
In addition to his work as a professor of medicine at Harvard Medical School and as director of the Lowe Center for Thoracic Oncology, Dr. Janne is also a translational thoracic medical oncologist at the Dana Farber Cancer Institute and scientific co-director at the Belfer Institute for Applied Cancer Sciences.
Dr Jänne’s research combines laboratory-based studies with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center on understanding and translating the therapeutic importance of oncogenic alterations in lung cancer. He has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations, and findings from his work have led to the development of several clinical trials. In addition, he led the first-in man clinical trial of the mutant selective EGFR inhibitor osimertinib (AZD9291) which was recently approved by the U.S. Food and Drug Administration.
Dr. Jänne has received several awards for his research including from Uniting Against Lung Cancer, the American Lung Association and the Bonnie J. Addario Lung Cancer Foundation. In 2008 he was elected as a member to the American Society of Clinical Investigation. He is also the recipient of the 2010 American Association of Cancer Research (AACR) Richard and Hinda Rosenthal Memorial Award and a member of the 2010 AACR Team Science Award.